News

GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases
The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These ...
Southern Syria exploded into the worst violence of post-Assad era. What that means for the region's future
Seven months of relative calm in Syria came to a bloody end last week, when what began as local skirmishes escalated into the ...
Sanofi’s SAR446597 Gains Fast Track Status and Vicebio Acquisition Announced
In July 2025, Sanofi announced that its SAR446597 therapy received fast track designation from the US FDA for treating geographic atrophy due to age-related macular degeneration, highlighting its ...